VolitionRX (VNRX) Projected to Announce Quarterly Earnings on Thursday

VolitionRX (NYSEAMERICAN:VNRX) is anticipated to release its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to post earnings of ($0.70) per share and revenue of $0.4150 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 8:30 AM ET.

VolitionRX (NYSEAMERICAN:VNRX) last issued its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27). The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.52 million.

VolitionRX Price Performance

VolitionRX stock opened at $0.72 on Wednesday. The stock’s 50 day moving average is $1.22 and its 200 day moving average is $2.83. The firm has a market cap of $6.17 million, a P/E ratio of -0.17 and a beta of 1.16. VolitionRX has a one year low of $0.66 and a one year high of $15.10.

Wall Street Analyst Weigh In

A number of analysts have weighed in on VNRX shares. Maxim Group reissued a “buy” rating and set a $4.00 target price on shares of VolitionRX in a research report on Thursday, June 18th. Benchmark restated a “hold” rating on shares of VolitionRX in a research report on Tuesday, June 2nd. D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th. Finally, Citigroup cut shares of VolitionRX to a “hold” rating in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.00.

Institutional Investors Weigh In On VolitionRX

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in shares of VolitionRX by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after purchasing an additional 85,816 shares in the last quarter. Armistice Capital LLC increased its position in VolitionRX by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after buying an additional 887,351 shares in the last quarter. Squarepoint Ops LLC bought a new stake in VolitionRX in the 4th quarter valued at about $34,000. Jane Street Group LLC bought a new stake in VolitionRX in the 4th quarter valued at about $28,000. Finally, Citadel Advisors LLC raised its stake in VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after buying an additional 135,775 shares during the period. 8.09% of the stock is owned by institutional investors.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.